16 Feb 2021 10:34
RNS Number : 2549P
Braveheart Investment Group plc
16 February 2021
16 February 2021
Braveheart Investment Group plc
("Braveheart" or the "Group")
Share price movement
Braveheart notes the recent share price rise. On 29 January 2021 Braveheart provided an update concerning progress to develop a COVID-19 test that Paraytec Limited is working on in conjunction with the University of Sheffield.
In the update it was noted that the pipeline of clinical samples was now fully operational and additional staff had been recruited to process samples for performance assessment. The update also stated that the results from this phase of clinical testing were expected by the end of February and this remains the case. Until the results of the testing are known there can be no certainty that the tests will be successful.
A further announcement will be made in due course.
| For further information: |
| | Braveheart Investment Group plc | Tel: 01738 587555 | Trevor Brown CEO | | | | Allenby Capital Limited (Nominated Adviser and Joint Broker) | Tel: 020 3328 5656 | David Worlidge / James Reeve / George Payne | | | | Peterhouse Capital Limited (Joint Broker) | Tel: 020 7469 0936 | Heena Karani / Lucy Williams | |
| |
| | |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCTFMMTMTJBBJB
Last checked at